Evidence map›Paper›PMID 31713054›Full record

ArticleJournal of artificial organs : the official journal of the Japanese Society for Artificial Organs2020

A case series: the outcomes, support duration, and graft function recovery after VA-ECMO use in primary graft dysfunction after heart transplantation.

Masashi Kawabori, Michael A Mastroianni, Yong Zhan, Frederick Y Chen, Hassan Rastegar, Kenneth G Warner, John Adam Reich, Amanda Vest, David DeNofrio, Gregory S Couper

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Masashi Kawabori1Cardiac Surgery, Cardiovascular Center, Tufts Medical Center, 800 Washington St, Boston, MA, 02111, USA. Kawabori.masashi@gmail.com.
Michael A Mastroianni1Cardiac Surgery, Cardiovascular Center, Tufts Medical Center, 800 Washington St, Boston, MA, 02111, USA. Michael.Mastroianni@tufts.edu.
Yong Zhan1Cardiac Surgery, Cardiovascular Center, Tufts Medical Center, 800 Washington St, Boston, MA, 02111, USA.
Frederick Y Chen1Cardiac Surgery, Cardiovascular Center, Tufts Medical Center, 800 Washington St, Boston, MA, 02111, USA.
Hassan Rastegar1Cardiac Surgery, Cardiovascular Center, Tufts Medical Center, 800 Washington St, Boston, MA, 02111, USA.
Kenneth G Warner1Cardiac Surgery, Cardiovascular Center, Tufts Medical Center, 800 Washington St, Boston, MA, 02111, USA.
John Adam ReichAnesthesiology, Critical Care Medicine, Tufts Medical Center, Boston, MA, USA.
Amanda VestCardiology, Cardiovascular Center, Tufts Medical Center, Boston, MA, USA.
David DeNofrioCardiology, Cardiovascular Center, Tufts Medical Center, Boston, MA, USA.
Gregory S Couper1Cardiac Surgery, Cardiovascular Center, Tufts Medical Center, 800 Washington St, Boston, MA, 02111, USA.
Tufts Medical Center · USTufts University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Primary graft dysfunction (PGD) is a rare complication associated with high mortality after heart transplantation, which may require veno-arterial extra-corporeal membrane oxygenation (VA-ECMO) support. A standardized definition for PGD was developed by the International Society of Heart and Lung Transplantation in 2014. Due to limited reports using this definition, the detailed outcomes after VA-ECMO support remain unclear. Therefore, we retrospectively analyzed our single-center outcomes of PGD following VA-ECMO support. Between September 2014 and August 2018, 160 patients underwent heart transplantation in our single center. Nine PGD patients required VA-ECMO support, with an incidence of 5.6%. Pre-operative recipient/donor demographics, intra-operative variables, timing of VA-ECMO initiation and support duration, graft function recovery during 30 days after heart transplant, VA-ECMO complications, and survival were analyzed. The indication for VA-ECMO support was biventricular failure for all nine patients. Six patients had severe PGD requiring intra-operative VA-ECMO, while two patients had moderate PGD and one patient had mild PGD requiring post-operative VA-ECMO. All cohorts were successfully decannulated in a median of 10 days. Survival to discharge rate was 88.9%. One-year survival rate was 85.7%. Left ventricular ejection fraction recovered to normal within 30 days in all PGD patients. Our study showed VA-ECMO support led to high survival and timely graft function recovery in all cohorts. Further larger research can clarify the detailed effects of VA-ECMO support which may lead to standardized indication of VA-ECMO support for PGD patients.

Indexed as

AdultAgedExtracorporeal Membrane OxygenationHeart FailureHeart TransplantationHumansMaleMiddle AgedPrimary Graft DysfunctionRecovery of FunctionRetrospective StudiesSurvival RateArtificial lung/ECMOHeart transplantationPGDPrimary graft dysfunctionVA-ECMO

Identifiers

PMID31713054
OpenAlexW2986018485

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.